|
Oxford BioDynamics PLC - Oxford-based biotechnology firm focused on discovery and development of epigenetic biomarkers Says its US reimbursement code for EpiSwitch is now available. EpiSwitch Checkpoint-inhibitor Response Test is a test which predicts a patient's likely response to immune checkpoint inhibitor therapy. It was first launched in the US in February.
Back in July, Oxford BioDynamics said it had been issued a proprietary laboratory code by the American Medical Association's Current Procedural Terminology Editorial Board for EpiSwitch.
Chief Operating Officer Thomas Guiel comments: ‘The availability of our unique reimbursement code is another milestone for us as well as the patients and their doctors. We are continuing our efforts to create a wider use of our predictive test within the healthcare system, and so facilitate a better understanding of the application of checkpoint inhibitors.’
Current stock price: 12.50 pence, up 8.7% on Monday in London
12-month change: down 72%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
